BRAF inhibitors: From the laboratory to clinical trials
Files
File version
Author(s)
Salajegheh, A
Smith, RA
Lam, AK-Y
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
1367117 bytes
File type(s)
application/pdf
Location
License
Abstract
BRAF is one of the most commonly mutated proto-oncogenes and plays a significant role in the development of numerous cancers of high clinical impact. Due to the commonality of BRAF mutations, a number of BRAF inhibitors have been developed as tools in the management of patients with cancers dependent on the action of mutant BRAF to drive cellular proliferation. In this review, we examine the current state of clinical trials and laboratory research concerning BRAF inhibitors in development and available for clinical use. We contrast the effectiveness of type-I and type-II BRAF inhibitors, the former typically showing much more restricted inhibitory selectivity and greater patient response rates.
Journal Title
Critical Reviews in Oncology/Hematology
Conference Title
Book Title
Edition
Volume
90
Issue
3
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
© 2014 Elsevier B.V. This is the author-manuscript version of this paper. Reproduced in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version.
Item Access Status
Note
Access the data
Related item(s)
Subject
Cardiovascular medicine and haematology
Oncology and carcinogenesis